Literature DB >> 10729317

Corticotrophin-releasing hormone (CRH) interacts with inflammatory prostaglandins and interleukins and affects the decidualization of human endometrial stroma.

E Zoumakis1, A N Margioris, C Stournaras, E Dermitzaki, E Angelakis, A Makrigiannakis, E Koumantakis, A Gravanis.   

Abstract

The hypothalamic neuropeptide, corticotrophin-releasing hormone (CRH), which is also produced by human endometrium, has been shown to induce its decidualization in vitro. This process, induced mainly by progesterone, has characteristics of an aseptic inflammatory reaction, and is modulated by locally produced pro-inflammatory factors. In humans, prostaglandin E(2) (PGE(2)) enhances while interleukin (IL)-1 inhibits the decidualizing effect of progesterone. The aim of the present work was to test the hypothesis that CRH might affect the decidualization of human endometrium interacting with these factors. Therefore, we studied its effects on the production of pro-inflammatory interleukins IL-1, IL-6 and of PGE(2) from human endometrial stromal cells in primary culture. The results strongly suggest that CRH decidualizes stromal cells, as judged by the appearance of cytokeratins and the production of prolactin, two established markers of decidualization. In parallel to its effect on decidualization, CRH also decreased the production of PGE(2), while it increased the production of IL-1 and IL-6. Exposure of endometrial stromal cells to IL-6 also caused decidualization. The data presented here suggest that endometrial CRH regulates the production of local modulators of decidualization, i.e. PGE(2), IL-1 and IL-6. We postulate that, through the regulation of these factors, CRH acts as a local fine-tuner of decidualization initiated by progesterone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729317     DOI: 10.1093/molehr/6.4.344

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  7 in total

1.  The production of interleukin-11 and decidualization are compromised in endometrial stromal cells derived from patients with infertility.

Authors:  Natalia Karpovich; Petra Klemmt; Jung Hye Hwang; J Enda McVeigh; John K Heath; David H Barlow; Helen J Mardon
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  An integrated map of corticotropin-releasing hormone signaling pathway.

Authors:  Tejaswini Subbannayya; Lavanya Balakrishnan; Granthali Sudarshan; Jayshree Advani; Santosh Kumar; Riaz Mahmood; Bipin Nair; Ravi Sirdeshmukh; Kanchan K Mukherjee; Sudhir N Umathe; Rajesh Raju; T S Keshava Prasad
Journal:  J Cell Commun Signal       Date:  2013-03-16       Impact factor: 5.782

Review 3.  The role of RAS in the pathogenesis of preeclampsia.

Authors:  Dinesh M Shah
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

4.  Galectin-1 overexpression in endometriosis and its regulation by neuropeptides (CRH, UCN) indicating its important role in reproduction and inflammation.

Authors:  Aikaterini Vergetaki; Udo Jeschke; Thomas Vrekoussis; Eirini Taliouri; Luca Sabatini; Evangelia A Papakonstanti; Antonis Makrigiannakis
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

Review 5.  Human Decidual Stromal Cells as a Component of the Implantation Niche and a Modulator of Maternal Immunity.

Authors:  Kameliya Vinketova; Milena Mourdjeva; Tsvetelina Oreshkova
Journal:  J Pregnancy       Date:  2016-04-28

6.  Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis.

Authors:  Annelyn Torres-Reverón; Leslie L Rivera-Lopez; Idhaliz Flores; Caroline B Appleyard
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

7.  Differential expression of CRH, UCN, CRHR1 and CRHR2 in eutopic and ectopic endometrium of women with endometriosis.

Authors:  Aikaterini Vergetaki; Udo Jeschke; Thomas Vrekoussis; Eirini Taliouri; Luca Sabatini; Evangelia A Papakonstanti; Antonis Makrigiannakis
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.